Treatment for Lymphoma

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Wilmot Cancer Institute, Rochester, NY
Lymphoma+15 More
Eligibility
Any Age
All Sexes
Eligible conditions
Select

Study Summary

This study is evaluating whether umbilical cord blood stem cells may help treat individuals with leukemia.

See full description

Eligible Conditions

  • Lymphoma
  • Aplastic Anemia
  • Myelodysplastic Syndromes
  • Multiple Myeloma
  • Tumors, Solid
  • Leukaemia (Chronic)
  • Acute Leukemia (Category)
  • Congenital Hematological Disorder
  • Metabolism Disorders
  • Immune Deficiency Disorders

Treatment Effectiveness

Effectiveness Estimate

1 of 3

Study Objectives

This trial is evaluating whether Treatment will improve 1 primary outcome and 4 secondary outcomes in patients with Lymphoma. Measurement will happen over the course of At 30 days and 100 days after transplant from the date of transplant until the date of documented acute GvHD..

Day 42
Engraftment of ANC and Platelets
Month 120
Incidence of chronic graft-versus-host disease
Day 100
Incidence of acute graft-versus-host disease
Month 120
Disease-free survival
Month 120
Rate of non-engraftment and of secondary graft failure

Trial Safety

Trial Design

0 Treatment Group

This trial requires 30 total participants across 0 different treatment group

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: at 30 days, 100 days, 6 months and yearly from the date of transplant until the date of documented graft failure or the subject's death up to 120 months.
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly at 30 days, 100 days, 6 months and yearly from the date of transplant until the date of documented graft failure or the subject's death up to 120 months. for reporting.

Who is running the study

Principal Investigator
J. L.
Jane Liesveld, Clinical Director, BMT Unit
University of Rochester

Closest Location

Wilmot Cancer Institute - Rochester, NY

Eligibility Criteria

This trial is for patients born any sex of any age. You must have received 2 prior treatments for Lymphoma or one of the other 15 conditions listed above. There are 10 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
Immunodeficiency disorders (e.g. Severe Combined Immunodeficiency, Wiskott-Aldrich Syndrome)
Congenital hematopoietic stem cell defects (e.g. Chediak-Higashi Syndrome, Congenital Osteopetrosis, Osteogenesis Imperfecta)
Metabolic disorders (e.g. Hurler's Syndrome)
Severe aplastic anemia
Acute Myelogenous Leukemia
Refractory to standard induction therapy (more than 1 cycle required to achieve remission)
Recurrent (in CR ≥ 2)
Treatment-related AML or MDS
Evolved from myelodysplastic syndrome
Presence of FLT3 abnormalities

Patient Q&A Section

Can hematologic diseases be cured?

"It was not possible to observe a complete remission. As the number of new cases increased, it was also difficult to achieve a continuous remission. Thus, hematological diseases should be considered as chronic illnesses." - Anonymous Online Contributor

Unverified Answer

What are common treatments for hematologic diseases?

"There are a multitude of treatment options for hematologic diseases. Chemotherapy and/or bone marrow transplantation in chronic myelogenous leukemia (CML) are very common. A variety of novel agents for solid tumors are increasingly becoming available. Some types of hematologic malignancies respond very well to specific chemotherapy regimens. Radiation is also sometimes used in the treatment of certain hematologic malignancies." - Anonymous Online Contributor

Unverified Answer

What are the signs of hematologic diseases?

"Hematologic disorders commonly present with nonspecific symptoms. A complete blood count and a hematocrit test seem to be optimal initial tests that are essential to determine etiology and initiate necessary treatments. Blood cultures should be part of the workup of such patients." - Anonymous Online Contributor

Unverified Answer

How many people get hematologic diseases a year in the United States?

"In this large population-based sample of US veterans, 1.4% (95% confidence interval 1.3-1.4) per year suffered from hematologic disease within 2 years of their diagnosis. Hematologic disease most frequently affected the elderly (61% of patients ages >80 years), whereas myeloid neoplasms (10% of patients) and malignant lymphoma (9% of patients) were most common among Hispanics." - Anonymous Online Contributor

Unverified Answer

What causes hematologic diseases?

"All hematologic diseases have many common, nonmutagenic causes. Most hematologic disorders can therefore be attributed to a single cause or few causes. However, one can imagine and try to explain, at least in part the genesis of the hematologic abnormalities observed in specific hematologic diseases.\n" - Anonymous Online Contributor

Unverified Answer

What is hematologic diseases?

"Hematologic diseases are a heterogeneous group of disorders that can be a result of the body's response to foreign materials, or an intentional treatment of diseases." - Anonymous Online Contributor

Unverified Answer

What is the latest research for hematologic diseases?

"The latest published studies have provided further insights into the mechanisms of various hematologic diseases. Specific strategies such as immunomodulatory therapy will hopefully increase survival and quality of life for patients with hematologic diseases." - Anonymous Online Contributor

Unverified Answer

How quickly does hematologic diseases spread?

"The study concluded that in a country with a stable, homogeneously distributed population, hematologic disease has a high potential to spread quickly due to small and widely interconnected blood or blood-forming organs, the contact between them and the common circulation system, and limited natural barriers, including high transportation of people and goods to places and areas with a high prevalence of such diseases." - Anonymous Online Contributor

Unverified Answer

What is the primary cause of hematologic diseases?

"Patients frequently attribute various causes to hematologic diseases which may not be an underlying cause. Further evaluation of these causes by hematologists could reduce misdiagnosis and, hopefully, improve patient outcomes." - Anonymous Online Contributor

Unverified Answer

What are the chances of developing hematologic diseases?

"There is a high prevalence of hematologic conditions and/or immune-related diseases in a group of patients undergoing surgery for gastrointestinal cancer. The rate of occurrence of these diseases is higher in patients with more severe gastroenterologic diseases." - Anonymous Online Contributor

Unverified Answer

How serious can hematologic diseases be?

"It is important that each patient have a complete evaluation for symptoms and signs of an underlying disease so as to detect this condition early and prevent it from progressing. Hematologists can help physicians to diagnose and treat these disorders: anemia; infection; multiple myeloma and leukemia; immune related diseases; anemia and autoimmune disorders; and blood disorders including anemia and thrombocytopenia." - Anonymous Online Contributor

Unverified Answer

What is the survival rate for hematologic diseases?

"Hematological diseases, in general, have a poor survival rate. The survival rate can be improved in certain types of hematological diseases. Survival rate can also be enhanced in individuals that have specific mutations (and/or mutations to different types of genes) and certain diseases. The survival rate of a particular type of hematological disease is defined by the specific survival rates for the disease, and by patients' overall health conditions. These disease specific survival rates vary by disease, while overall survival rates will vary across all hematologic diseases. While the specific survival rate for hematological diseases can be found online, a survival rate for all individuals, by condition, can also be found online by using [Power] (http://www." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
See if you qualify for this trial
Get access to this novel treatment for Lymphoma by sharing your contact details with the study coordinator.